Open AccessOral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
Author(s) -
Sotaro Sadahiro,
Toshiyuki Suzuki,
Kazutake Okada,
Gota Saito,
Hiroshi Miyakita,
Takashi Ogimi,
Lin Fung Chan,
Yutaro Kamei
Publication year - 2020
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000507293
Subject(s) - bevacizumab , irinotecan , medicine , folfiri , clinical endpoint , colorectal cancer , fluorouracil , chemotherapy , phases of clinical research , gastroenterology , surgery , randomized controlled trial , cancer
FOLFIRI plus bevacizumab have been widely used as first-line treatment for metastatic colorectal cancer (mCRC). Pharmacokinetics and pharmacodynamics suggested a low dose of irinotecan given as a long-term infusion is expected to enhance antitumor activity. We conducted a randomized phase II study to compare oral S-1 with a 24-h infusion of irinotecan plus bevacizumab versus FOLFIRI plus bevacizumab.